• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biogen adds management to hemophilia spin-off Bioverativ

Biogen adds management to hemophilia spin-off Bioverativ

November 21, 2016
CenterWatch Staff

Biogen has announced the addition of two members to the executive management team of Bioverativ, Biogen’s planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer of Bioverativ, and John T. Greene will serve as executive vice president and chief financial officer of Bioverativ. The spin-off of Bioverativ is on track to be completed in early 2017.

“Biogen is committed to positioning Bioverativ for success as it prepares to carry forward our dedication to the hemophilia community,” remarked George A. Scangos, Ph.D., chief executive officer of Biogen. “Rogerio and John will be instrumental players in that success, alongside the rest of the executive team.”

“Rogerio’s expertise in the industry and extensive knowledge of the rare disease space will be critical as we work to deliver transformative medicines to patients,” said John Cox, chief executive officer of Bioverativ. “And, given John’s strong track record of fiscal and operational management across all of the major disciplines within finance, I am confident in his ability to lead our global finance organization and be an excellent representative for our shareholders.”

Dr. Vivaldi has more than 20 years of experience in delivering orphan products to patients worldwide, most notably during his tenure at Genzyme, where he applied his medical and professional expertise to lead the company's rare disease business and earned a reputation as a passionate advocate for patients. Most recently, he served as chief commercial officer at Spark Therapeutics, a gene therapy company, and was co-founder, president and CEO of Minerva Neurosciences.

He received his medical degree from Universidade do Rio de Janeiro Medical School, and completed his residency in endocrinology at Universidade do Estado do Rio de Janeiro and his fellowship at Mount Sinai Hospital Center in New York in the department of genetics. He received his MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro.

Dr. Vivaldi will be responsible for building and leading all aspects of Bioverativ’s commercial organization, including oversight of sales and marketing for the franchise’s lead products, ELOCTATE and ALPROLIX, extended half-life therapies for the treatment of hemophilia A and hemophilia B, respectively. He will report to Bioverativ CEO John Cox.

“Bioverativ is a unique opportunity to join a new company with a strong commercial business, growing pipeline and an experienced team dedicated to delivering results for patients, providers and caregivers,” said Dr. Vivaldi. “I am passionate about improving lives through innovative therapies and ardent patient advocacy, and believe Bioverativ shares this vision.”

Greene joins Bioverativ from Willis Group, where he served as chief financial officer, enhancing business analytics and company performance while helping to execute on an ambitious merger and acquisition program. Previously, he was chief financial officer for HSBC Holdings, earning positions of increasing responsibility over eight years with the company, including Chief Financial Officer for the Global Retail Bank and Wealth Management business. Earlier in his career, Mr. Greene spent 12 years in various roles at General Electric. He earned his undergraduate degree from the State University of New York and an MBA from Northwestern University’s Kellogg School of Management.

“I am excited about the opportunity to apply my experience to a field that makes a meaningful difference in the lives of those it serves,” said Greene. “I look forward to working with the Bioverativ leadership team to create a leading organization that I believe is well-positioned for growth based on world-class science and a focus on addressing serious unmet needs in the blood disorders community.”

Greene will be responsible for all financial and fiscal management of Bioverativ’s operations, with oversight for the company’s finance, information technology and technical operations functions. He will also work closely with business development, and research and development to grow the business. He will also report to Mr. Cox.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing